Editas Medicine, Inc.

Listed Company

EDITCIK 0001650664NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

$40.52M

Net Income

$-160.10M

Total Assets

$186.53M

Equity

$27.29M

Shares Out

97.87M

Op. Cash Flow

$-165.24M

Business

Editas Medicine, Inc. is a gene editing company developing genomic medicines using CRISPR/Cas9 and CRISPR/Cas12a technologies to treat serious diseases. It develops therapeutic candidates and delivery systems, including engineered nucleases, guide RNAs, lipid nanoparticle (LNP) and viral delivery modalities, and ex vivo editing approaches. Its activities are organized around in vivo gene editing programs (hematopoietic stem cells, liver and other tissues), discovery and preclinical development, licensing and collaborations, and cellular therapy partnerships. It distributes and advances programs through collaborations, in‑licensing, clinical development and third‑party manufacturing across global regulatory markets.

Summary from filing dated 2025-03-05

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Collaboration and other research and development revenues	41	32	78	20	26
Research and development	90	199	178	175	143
General and administrative	50	72	70	71	76
Restructuring and impairment charges	61	12	—	—	—
Total operating expenses	201	283	247	246	219
Operating loss	−160	−251	−169	−226	−193
Interest expense related to sale of future revenues	−6	−2	—	—	—
Interest income, net	8	16	18	6	607,000
Other expense, net	−2	−3,000	−2	0	37,000
Total other income (expense), net	−50,000	14	16	6	644,000
Net loss	−160	−237	−153	−220	−193
Net loss per share, basic (in dollars per share)	−1.8	−2.88	−2.02	−3.21	−2.85
Net loss per share, diluted (in dollars per share)	−1.8	−2.88	−2.02	−3.21	−2.85
Weighted-average common shares outstanding, basic (in shares)	89	82	76	69	68
Weighted-average common shares outstanding, diluted (in shares)	89	82	76	69	68

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	147	132	124	142	204
Marketable securities	0	138	199	203	296
Accounts receivable	15	16	10	5	267,000
Prepaid expenses and other current assets	2	3	8	7	7
Total current assets	164	289	341	357	507
Property and equipment, net	4	14	12	16	17
Right-of-use assets	16	33	34	44	26
Restricted cash and other non-current assets	3	5	9	5	7
Total assets	187	342	499	514	677
Accounts payable	3	5	8	10	5
Accrued expenses	33	46	35	31	20
Liability for sale of future revenues, current	5	5	0	—	—
Deferred revenue, current	0	6	8	8	11
Operating lease liabilities, current	6	15	12	11	10
Total current liabilities	46	77	63	60	47
Operating lease liabilities, net of current portion	12	20	24	33	16
Liability for sale of future revenues, net of current portion	54	52	0	—	—
Deferred revenue, net of current portion	45	54	61	61	61
Other non-current liabilities	3	3	2	0	—
Total liabilities	159	207	150	154	124
Commitments and contingencies (Note 8)	—	—	—	—	—
Common stock, par value (in dollars per share)	0	0	0	0	0
Preferred stock, $0.0001 par value per share: 5,000,000 shares authorized; no shares issued or outstanding	0	0	0	0	—
Common stock, $0.0001 par value per share: 390,000,000 and 195,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; 97,866,996 and 82,734,696 shares issued and outstanding, at December 31, 2025 and December 31, 2024, respectively	10,000	8,000	8,000	7,000	7,000
Additional paid-in capital	1,656	1,602	1,580	1,442	1,412
Accumulated other comprehensive income	0	268,000	198,000	−4	−493,000
Accumulated deficit	−1,600	−1,468	−1,231	−1,078	−858
Total stockholders equity	27	134	349	361	554
Total liabilities and stockholders equity	187	342	499	514	677

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation expense	10	21	20	29	43
Depreciation	5	6	6	6	5
Loss on disposal of fixed assets	2	149,000	0	0	—
Net accretion of discounts on marketable securities	−902,000	−6	−5	−724,000	2
Interest related to sale of future revenues	6	2	—	—	—
Impairment of held for sale assets	4	0	—	—	—
Other non-cash items, net	−449,000	−415,000	2	0	0
Accounts receivable	1	−6	−5	−5	6
Prepaid expenses and other current assets	1	4	−197,000	−137,000	4
Right-of-use assets	12	1	10	−17	10
Other non-current assets	1	3	−3	2	−2
Accounts payable	−3	−2	−1	4	−1
Accrued expenses	−13	12	4	11	−4
Accrued interest on sale of future revenues	−2	0	—	—	—
Deferred revenue	−16	−8	0	−3	−23
Operating lease liabilities	−12	−2	−7	18	−10
Other non-current liabilities	192,000	1	—	—	—
Net cash used in operating activities	−165	−210	−132	−177	−164
Purchases of property and equipment	−607,000	−9	−5	−4	−8
Proceeds from the sale of equipment	269,000	0	0	18,000	0
Purchases of marketable securities	0	−86	−259	−315	−409
Proceeds from maturities of marketable securities	139	257	260	433	362
Net cash provided by investing activities	139	162	−4	114	−54
Repayment on sale of future revenues	−3	0	—	—	—
Proceeds from offering of common stock, net of issuance costs	43	0	117	0	249
Proceeds from sale of future revenues, net	0	55	—	—	—
Proceeds from exercise of stock options	70,000	193,000	41,000	305,000	31
Issuance of common stock under benefit plans	424,000	590,000	919,000	979,000	1
Net cash provided by financing activities	40	56	118	1	282
Net increase (decrease) in cash, cash equivalents, and restricted cash	14	8	−18	−62	64
Fixed asset additions included in accounts payable and accrued expenses	0	65,000	845,000	1	749,000
Cash paid in connection with operating lease liabilities	15	18	12	15	13
Remeasurement of operating lease liabilities and right-of-use assets due to lease modification	766,000	794,000	3	25	11
Commencement of right-of-use asset	0	8	0	5	—
Modification of right-of-use asset	0	3	0	0	—
Non-cash termination of right-of-use asset	5	0	—	—	—
Cash paid for interest	2	0	—	—	—
Issuance costs associated with the sale of future revenues included in accounts payable and accrued expenses	0	1	0	0	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro